Article Contents ::
- 1 The Brand Name REDITUX Has Generic Salt :: RITUXIMAB
- 2 REDITUX Is From Company Dr.Reddy’S Priced :: Rs. 9999
- 3 REDITUX have RITUXIMAB is comes under Sub class Drugs for Arthritis,Osteoporosis of Main Class Musculoskeletal Disorders , Pain
- 4 Main Medicine Class:: Musculoskeletal Disorders , Pain Sub Medicine Class :: Drugs for Arthritis,Osteoporosis
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name REDITUX Has Generic Salt :: RITUXIMAB
REDITUX Is From Company Dr.Reddy’S Priced :: Rs. 9999
REDITUX have RITUXIMAB is comes under Sub class Drugs for Arthritis,Osteoporosis of Main Class Musculoskeletal Disorders , Pain
Main Medicine Class:: Musculoskeletal Disorders , Pain Sub Medicine Class :: Drugs for Arthritis,Osteoporosis
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Non-Hodgkin’s lymphoma; follicular lymphoma
Drug Dose ::
Adult: IV Non-Hodgkin’s lymphoma; Refractory or relapsed follicular lymphoma As a single agent: 375 mg/m2 via infusion at 50 mg/hr once wkly for 4 doses. May increase rate slowly. If tolerated, may start subsequent infusions at 100 mg/hr and increase slowly. Max rate: 400 mg/hr. W/ cyclophosphamide, vincristine, and prednisolone for follicular lymphoma (CVP) or w/ cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for diffuse large B-cell lymphoma: 375 mg/m2 on day 1 of each 21-day cycle for 8 doses. Patients who were treated w/ 6-8 cycles of CVP chemotherapy and have not progressed: May give 375 mg/m2 once wkly for 4 doses, may repeat 6 mthly up to 16 doses. Maintenance for responders to induction chemotherapy: 375 mg/m2 once 3 mthly until disease progression or a max period of 2 yr. Rheumatoid arthritis Two 1g infusion doses, separated by 2 wk.
Lactation. Type I hypersensitivity or anaphylactic reactions to murine proteins or component of the formulation.
Drug Precautions ::
Extensive tumor burden, pulmonary tumor infiltration or pulmonary insufficiency; history of cardiac disease; effective contraception during and up to 12 mth after treatment; pregnancy. Monitor CBC and platelet counts regularly. Premedication with analgesics, antihistamines and corticosteroids may be recommended. Monitor for signs of active infection or hepatitis in hepatitis B carriers. Discontinue treatment if viral hepatitis develops.
Drug Side Effects ::
Fever and rigors. Pruritus, skin rashes, dyspnoea, bronchospasm, angioedema, transient hypotension, and flushing, tumor lysis syndrome, respiratory failure, thrombocytopenia, neutropenia, anaemia. Hypersensitivity reactions. Potentially Fatal: Pulmonary or cardiac toxicity during infusion; severe mucocutaneous reactions; severe cytokine release syndrome associated with tumor lysis syndrome. Toxic epidermal necrolysis.
Pregnancy category ::
Drug Mode of Action ::
Rituximab is a chimeric monoclonal antibody to CD20 antigen which regulates cell cycle initiation. It binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity.
Drug Interactions ::
Increased risk of renal toxicity w/ cisplatin. Potentially Fatal: May decrease the efficacy of vaccines and increase the risk of infections in patients immunised w/ live vaccines.